EVOLVE Short DAPT with the SYNERGY BP Stent - YouTube
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Can We Define High-risk DAPT Patients in USA Practice? - ppt download
BostonSci Cardiology on X: "See how SYNERGY™ BP Stent performed 12-months post-DAPT discontinuation in the EVOLVE Short #DAPT Trial: https://t.co/fQIpaJOGOC Safety Info: https://t.co/aA0ofN4r9t https://t.co/lrWq5mVKBT" / X
Managing Anticoagulation and Dual Antiplatelet Therapy in Patients with Active Bleed or Upcoming Procedure: A Scoping Review | Published in Journal of Brown Hospital Medicine
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
Antiplatelet therapy after percutaneous coronary intervention - EuroIntervention
EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case | tctmd.com
XIENCE Stent: Protecting Patients with Short DAPT Needs | Abbott
Bleeding and Ischemic Risk Prediction in Patients With High Bleeding Risk (an EVOLVE Short DAPT Analysis) - ScienceDirect
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
JCM | Free Full-Text | Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents
Three-month DAPT after PCI with Synergy stent supported in EVOLVE Short DAPT trial - Cardiovascular News
EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent | tctmd.com
SYNERGY EVOLVE Short DAPT Begins Enrollment - Boston Scientific
EVOLVE Short DAPT with the SYNERGY BP Stent - YouTube
Another Coronary Stent for Patients at High Bleeding Risk∗ | JACC: Cardiovascular Interventions
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation - ScienceDirect
Studying DAPT – SYNERGY Stent - Boston Scientific
Davide Capodanno on X: "My editorial to the EVOLVE Short DAPT study, from @ajaykirtane and colleagues (congratulations!). Interesting result and insightful data in a rapidly changing scenario that has more to say.
Session evaluation and key learnings
EVOLVE & EVOLVE II Clinical Trial Results - Boston Scientific
Managing Anticoagulation and Dual Antiplatelet Therapy in Patients with Active Bleed or Upcoming Procedure: A Scoping Review | Published in Journal of Brown Hospital Medicine
Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
